Evidence map›Paper›PMID 41822483›Full record

ArticleFrontiers in immunology2026

Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohort.

Caroline Brackett, Lu Zhang, Bich T N Do, Saman Baral, Leigh H Fisher, William O Hahn, Alexander J Carnacchi, Sir'Tauria Hilliard, Shuying S Li, Lakshmanane Premkumar and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Caroline BrackettDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
Lu ZhangDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
Bich T N DoDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
Saman BaralDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
Leigh H FisherVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
William O HahnVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Alexander J CarnacchiDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
Sir'Tauria HilliardDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
Shuying S LiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, United States.
Alexander L GreningerVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Ollivier HyrienVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Kelly E SeatonDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.
Georgia D TomarasDepartments of Surgery and Integrative Immunobiology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, United States.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

Introduction: Understanding the role of mucosal immune responses in preventing coronavirus replication is essential for the development of broad-spectrum therapeutics and vaccines capable of interrupting transmission. Investigating the relationship between mucosal antibodies and viral shedding may provide critical insights into protective mechanisms against SARS-CoV-2 and inform strategies for enhancing mucosal immunity. Methods: In a subset of the larger CoVPN 5001 cohort, 143 participants from the US, Mexico, and South America were characterized as either short (<7 days), intermediate (7-21 days), or prolonged (>21 days) virus shedders based on RT-qPCR measurements over the first month of acute SARS-CoV-2 infection. We measured systemic circulating serum IgA and secretory IgA (SIgA) in serially collected nasal lavage fluids to 15 SARS-CoV-2 antigens, including spike variants, receptor binding domain (RBD), and N-terminal Domain (NTD) and evaluated the relationship between antibody titers and duration of viral shedding using multivariate and binary logistic regression modeling. We also assessed antibody responses to RBD proteins of endemic alpha and beta coronaviruses to compare variations in antibody kinetics throughout the course of infection. Results: We found that increased serum IgA and mucosal secretory IgA antibody titers during the earliest phase of acute infection were associated with decreased viral shedding duration, with nasal IgA responses to the spike NTD being the strongest factor associated with viral shedding (adjusted p<0.1). In contrast, antibody titers against endemic human coronaviruses remained stable throughout the course of infection, consistent with a specific role for newly elicited SARS-CoV-2 antibodies in virus control. Discussion: These findings demonstrate that early rises in serum and mucosal IgA titers are associated with reduced duration of viral shedding. Notably, nasal secretory IgA responses targeting the spike N-terminal domain were most strongly associated with shorter shedding, suggesting a potentially protective role for SARS-CoV-2-specific nasal IgA during acute SARS-CoV-2 infection. These results highlight the importance of mucosal immunity for limiting viral transmission and shedding, offering future insights for pan-coronavirus therapeutics and vaccine development aimed for enhancing SARS-COV-2 mucosal antibody responses.

Indexed as

Antibodies, ViralCOVID-19Immunoglobulin A, SecretoryNasal MucosaSARS-CoV-2Virus SheddingAdultCohort StudiesFemaleHumansImmunity, MucosalMaleMiddle AgedNasal Lavage FluidSpike Glycoprotein, CoronavirusAntibodies, ViralImmunoglobulin A, SecretorySpike Glycoprotein, Coronavirusmucosal IgA responsesSARS-CoV-2secretory IgAserum IgAviral shedding duration

Identifiers

PMID41822483
PMCPMC12975920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.